- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
- Details
- Alicia Morgans interviews Omar El-Taji and Ashwin Sachdeva about their JAMA Oncology publication on cardiovascular risks associated with androgen receptor signaling inhibitors (ARSIs) in prostate cancer treatment. Their meta-analysis reveals that ARSIs significantly increase the risk of cardiovascular events across all stages of prostate cancer, with abiraterone and enzalutamide showing the highes...
|
- Details
- Zach Klaassen interviews Karen Hoffman about the PROSTATE-IQ trial, which aims to reduce the burden of androgen deprivation therapy (ADT) in men receiving salvage radiotherapy for prostate cancer. The trial incorporates the ArteraAI Prostate Test to stratify patients and explores alternative treatment strategies, including the use of apalutamide. Dr. Hoffman explains that the study focuses on impr...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Zach Klaassen and Geoffrey Johnson discuss the SECuRE trial, a phase 1-2 dose escalation expansion study of a PSMA-targeted radiopharmaceutical for prostate cancer using copper 67. This innovative therapy boasts a unique chelator, enhancing drug delivery and reducing systemic leakage. Early results demonstrate promising efficacy and safety, with notable responses observed in patients, including co...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Matthew Smith presents the primary analysis of the CYCLONE 2 trial. This global randomized controlled trial investigated the combination of abemaciclib, a CDK4/6 inhibitor, with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the promising biological rationale and preclinical evidence suggesting potential benefits, the trial did...
|
- Details
- Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. The trial involved administering CAR T cells, initially without and th...
|
- Details
- Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. Initial findings reveal that veterans with mental health issues are less frequently diagnosed with prostate...
|
- Details
- Zach Klaassen and Stacy Loeb discuss the IMPLEMENT Study, which investigates the underutilization of treatment intensification in metastatic hormone-sensitive prostate cancer. Despite guidelines recommending this approach, it is used in less than a third of cases. Phase one of the study identified barriers like limited knowledge of clinical trials and concerns about using up treatment options earl...
|
